Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
This was a multicenter, Phase 1, standard 3+3 dose-escalation study to evaluate the safety and anti-neoplastic activity of moxetumomab pasudotox in relapsed or refractory participants with chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL) or Small Lymphocytic Lymphoma (SLL).
Critère d'inclusion
- Leukemia, Lymphoma, Chronic Lymphocytic,Leukemia, Prolymphocytic Leukemia, Small,Lymphocytic Lymphoma, Moxetumomab Pasudotox